Photo from wikipedia
One of the puzzling observations from anti–amyloid-β therapeutic trials for Alzheimer disease (AD) has been that treated arms fail to show preservation of brain volume. In this issue of Neurology®,… Click to show full abstract
One of the puzzling observations from anti–amyloid-β therapeutic trials for Alzheimer disease (AD) has been that treated arms fail to show preservation of brain volume. In this issue of Neurology®, Alves et al.1 presented a meta-analysis of anti–amyloid-β therapies and show that the agents do not slow the rate of brain volume loss. Depending on the class of drug, these new agents can even accelerate loss of whole-brain and hippocampal volume and increase ventricular volume. This association has been seen with some of the beta-secretase inhibitors and with several of the antiamyloid monoclonal antibodies.
Journal Title: Neurology
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!